The shares last traded at 74c, having reached a record 79c on March 12 and have soared 289% from the rights issue price.

Dunedin-based bladder cancer detection test inventor announces the registration of its own diagnostic laboratory in Pennsylvania.

Can the dream run by some of New Zealand's top companies continue?

Revenue climbs 29% to $325,000, though just $11,000 of that is from external customers.